KLRA
Kailera Therapeutics, Inc. Common Stock
Nasdaq · usd
Kailera Therapeutics, Inc. Common Stock (KLRA) trades at $11.62 (-4.75%) as of 7:30:03 PM EST on Nov 18, 2026, -8.53% over the past month. Market cap is $1.53B, with 7.8 days to cover in short interest.
Stock performance
How Kailera Therapeutics, Inc. Common Stock (KLRA) stock has performed from one day to one year, with its 52-week range.
- 1D
- -3.36%
- 1W
- -18.01%
- 1M
- -8.53%
- YTD
- -54.65%
- 1Y
- -54.65%
- 52-wk range
- $9.76 – $28.23
Key statistics
Today's trading snapshot for KLRA: day range, open, previous close, volume and market cap.
- Day range
- $11.79 – $12.51
- Open
- $12.17
- Prev close
- $12.20
- Volume
- 418.8K
- Market cap
- $1.53B
- Shares out
- 129.85M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Kailera Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 1.48
- P/FCF
- —
- ROE
- -31.6%
- ROA
- -30.1%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 18, 2026
8-K filings
Material corporate events Kailera Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 4, 2026
On November 4, 2026, Kailera Therapeutics, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2026.
- Bylaw amendmentApr 20, 2026
On April 20, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company became effective. The Amended and Restated Bylaws amended and restated the Company's prior bylaws in their entirety to, among other things: (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings; (ii) establish procedures relating to the nomination of directors; and (iii) conform to the amended provisions of the Restated Certificate.
KLRA short interest
How heavily KLRA is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 7.8
- Short interest
- 8.16M
- Avg volume
- 1.04M
As of · reported to FINRA twice monthly.
KLRA news
The latest news and headlines about Kailera Therapeutics, Inc. Common Stock (KLRA).
- 3 Under-the-Radar Stocks to Buy and Hold for a DecadepositiveThe Motley Fool· Jun 16, 2026
- Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026positiveGlobeNewswire Inc.· Jun 5, 2026
- Is Kailera Therapeutics a Buy After Its Sizzling IPO?neutralThe Motley Fool· May 16, 2026
- Kailera Therapeutics' Strong IPO Validates "NewCo" StrategypositiveBenzinga· Apr 23, 2026
- Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharespositiveBenzinga· Apr 20, 2026
Frequently asked questions
What is the Kailera Therapeutics, Inc. Common Stock (KLRA) stock price today?
Kailera Therapeutics, Inc. Common Stock (KLRA) is trading at $11.62 (-4.75% on the day) as of 7:30:03 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Kailera Therapeutics, Inc. Common Stock?
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity.
What is the short interest in KLRA?
As of Oct 30, 2026, KLRA has 8.16M shares short and 7.8 days to cover.
What exchange is KLRA listed on?
Kailera Therapeutics, Inc. Common Stock (KLRA) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of KLRA with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a KLRA analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.